{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470478690
| IUPAC_name = 1-(2-deoxy-β-<small>L</small>-''erythro''-pentofuranosyl)-5-methylpyrimidine-2,4(1''H'',3''H'')-dione
| image = Telbivudine structure.svg
<!--Clinical data-->
| tradename = Tyzeka
| Drugs.com = {{drugs.com|monograph|telbivudine}}
| MedlinePlus = a607045
| licence_EU = Sebivo
| licence_US = Tyzeka
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = B
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = Low (3.3% ''[[in vitro]]'')
| metabolism = Nil
| elimination_half-life = 40 to 49 hours (terminal phase)
| excretion = [[Kidney|Renal]]
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 3424-98-4
| ATC_prefix = J05
| ATC_suffix = AF11
| PubChem = 159269
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01265
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 140081
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2OC4HKD3SF
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 374731
<!--Chemical data-->
| C=10 | H=14 | N=2 | O=5
| molecular_weight = 242.23 g/mol
| smiles = O=C/1NC(=O)N(\C=C\1C)[C@H]2O[C@H]([C@H](O)C2)CO
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IQFYYKKMVGJFEH-CSMHCCOUSA-N
| synonyms = 1-(2-deoxy-β-<small>L</small>-ribofuranosyl)-5-methyluracil<br>β-<small>L</small>-2-deoxythymidine<br>β-<small>L</small>-thymidine (LdT)<br>1-[(2''S'',4''R'',5''S'')-4-hydroxy-5-hydroxymethyltetrahydrofuran-2-yl]-5-methyl-1''H''-pyrimidine-2,4-dione
}}
'''Telbivudine''' is an [[antiviral drug]] used in the treatment of [[hepatitis B]] infection. It is marketed by Swiss pharmaceutical company [[Novartis]] under the trade names '''Sebivo''' (Europe) and '''Tyzeka''' (United States). [[Clinical trial]]s have shown it to be [[statistical significance|significantly]] more effective than [[lamivudine]] or [[adefovir]], and less likely to cause resistance.<ref name=Lai1>{{cite journal  |vauthors=Lai CL, Leung N, Teo EK, etal |title=A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B |journal=Gastroenterology |volume=129 |issue=2 |pages=528–36 |year=2005 |pmid=16083710 |doi=10.1016/j.gastro.2005.05.053}}</ref><ref name=NEJM>{{cite journal  |vauthors=Lai CL, Gane E, Liaw YF, etal |title=Telbivudine versus lamivudine in patients with chronic hepatitis B |journal=[[New England Journal of Medicine|N Engl J Med]] |volume=357 |issue=25 |pages=2576–88 |year=2007 |pmid=18094378 |doi=10.1056/NEJMoa066422}}</ref><ref>{{cite journal  |vauthors=Chan HL, Heathcote EJ, Marcellin P, etal |title=Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial |journal=[[Annals of Internal Medicine|Ann Intern Med]] |volume=147 |issue=11 |pages=745–54 |date=4 December 2007|pmid=17909201 |url=http://www.annals.org/cgi/content/full/147/11/745 |doi=10.7326/0003-4819-147-11-200712040-00183}}</ref> However, HBV signature resistance mutation M204I (a change from methionine to isoleucine at position 204 in the reverse transcriptase domain of the hepatitis B polymerase)  or L180M+M204V have been associated with Telbivudine resistance.<ref>{{cite journal|pmc=2762437 | pmid=19851526 | volume=5 | title=Safety and efficacy of telbivudine for the treatment of chronic hepatitis B | journal=Ther Clin Risk Manag | pages=789–98 | vauthors=Osborn MK}}</ref>

Telbivudine is a synthetic [[thymidine]] [[β-L-nucleoside analogue]]; it is the [[Stereoisomerism|<small>L</small>-isomer]] of thymidine. Telbivudine impairs hepatitis B virus (HBV) DNA replication by leading to chain termination. It differs from the natural nucleotide only with respect to the location of the sugar and base moieties, taking on an levorotatory configuration versus a dextrorotatory configuration as do the natural deoxynucleosides.<ref>{{cite journal|pmc=2762437 | pmid=19851526|volume=5|journal=Ther Clin Risk Manag|pages=789–98|title=Safety and efficacy of telbivudine for the treatment of chronic hepatitis B|vauthors=Osborn MK}}</ref> It is taken orally in a dose of 600&nbsp;mg once daily with or without food.

==References==
{{Reflist}}

==External links==
*[http://www.tyzeka.com/ Tyzeka official website] run by [[Novartis]] Pharmaceuticals Corporation
*[http://www.rxlist.com/cgi/generic/tyzeka.htm Telbivudine] entry in RxList
*[http://www.emea.europa.eu/humandocs/PDFs/EPAR/sebivo/H-713-PI-en.pdf Sebivo Summary of Product Characteristics] (from the EMEA website)

{{Antivirals}}

[[Category:Antivirals]]
[[Category:Pyrimidinediones]]
[[Category:Nucleosides]]


{{antiinfective-drug-stub}}